Hemodialysis is a medical technique used when kidney function is between 10% and 15%. In this surgery, an artificial kidney known as a dialyzer is utilized to filter extra fluid and toxins from the blood and restore the proper balance of electrolytes. It enhances kidney function by removing waste materials like urea and creatinine from the blood. Additionally, it helps control blood pressure levels and maintains a healthy amount of calcium, salt, and potassium in the circulatory system.
The market worth of hemodialysis in 2021 was USD 85.49 million, and it will be worth USD 130.36 million by 2030, growing at a 5.1% CAGR During the forecast period.
The two main causes of kidney damage are diabetes and cardiovascular disease. Thus, the rising incidence of diabetes and hypertension will help hemodialysis gain more acceptance.
Table of Contents
Major element stimulating the market’s expansion is the increasing prevalence of various ailments, including End-Stage Renal Disease (ESRD) and Chronic Kidney Disease (CKD), throughout the world. These illnesses are typically brought on by diabetes, excessive drunkenness, excessive drug use, high blood pressure, and hypertension. In such circumstances, there is also a gradual loss of renal function, which results in deteriorating health and nerve damage. Hemodialysis helps to restore nutritional health and stabilize blood pressure levels. The use of hemodialysis equipment has also expanded due to growing consumer knowledge of the advantages of early diagnosis and treatment of kidney illnesses.
Hemodialysis uses a lot of resources because the equipment is expensive and the supplies are scarce. Additionally, skilled personnel is required for dialysis. A year of hemodialysis can cost up to $72,000, whereas a year of peritoneal dialysis can cost around $53,000, according to the US Renal Data System.
The number of people receiving dialysis worldwide is steadily increasing, particularly in low- and middle-income nations. The demand for dialysis will rise as CKD and treatment alternatives become more widely known. The International Society of Nephrology’s Global Kidney Health Atlas 2019 predicts that by 2030, there will be a 9.1 million-person shortage of hemodialysis, up from 7.1 million in 2010.
On the basis of the stage of disease, the market is segment into CKD (chronic Kidney Disease) and ESRD (End-Stage Renal Disease). The CKD (Chronic Kidney Disease) segment led the market with the maximum revenue share. The last and most advanced stage of chronic kidney disease is known as an end-stage renal disease (ESRD). Patients with end-stage renal failure require dialysis or a kidney transplant. According to the United States Renal Data System’s Annual Data Report, Medicare spent more than $120 million on patients with CKD ($84 billion) and ESRD ($36 billion) in 2017.
On the basis of end-user, the market is segment into home hemodialysis, conventional hemodialysis, and others. Due to the widespread adoption of hemodialysis therapy compared to peritoneal dialysis among patients with end-stage renal illness and chronic kidney disease, conventional (in-center) hemodialysis is poise to take a sizable chunk of the market. In-center hemodialysis (HD) is when a patient receives treatment at a dialysis facility from a staff of nurses and technicians.
North America ruled the market with a significant revenue share and will grow at a 4.5% CAGR during the forecast period. The rising rates of advanced renal disease and diabetes in the area are to blame for the increased proportion. Over 661,000 Americans have kidney failure, according to the National Kidney Foundation, of whom roughly 468,000 are receiving regular dialysis, and 193,000 have had a kidney transplant. The Centers for Disease Control & Prevention predict that 37 million adult Americans will have chronic kidney disease (CKD) in 2019.
- Merck KGaA
- Asahi Kasei
- Becton, Dickinson, and Company
- Baxter & Gambro
- DaVita Inc
The market worth of hemodialysis in 2021 was USD 85.49 million. And it will be worth USD 130.36 million by 2030, growing at a 5.1% CAGR During the forecast period. The primary drivers influencing the growth of the market include the rising prevalence of diseases. Including End-Stage Renal Disease (ESRD) and Chronic Kidney Disease (CKD) around the world. As well as the scarcity of available kidneys for transplants. The demand for the product is also greatly increase by numerous technological advancements. Such as the advent of small devices that may easily be use for home-based treatments.
Hormone Replacement Therapy Market Report – The global hormone replacement therapy market will witness a robust CAGR of 7.83%, valued at $24.97 billion in 2021. Expected to appreciate and reach $49.25 billion by 2030, confirms Strategic Market Research.